Drug Trial Radar · NCT06980805
A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)
Last checked: Nov 19, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
56
Planned (sponsor's estimate)
Start
Feb 19, 2025
Primary completion
Oct 2026
Study completion Apr 2027
Sponsor
- Lead sponsor
- Immunovant Sciences GmbHIndustry
- Sponsor type
- Industry
- First posted
- May 20, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to evaluate the efficacy, safety, and tolerability of IMVT-1402 in participants with Cutaneous Lupus Erythematosus. The study will consist of 3 periods: Period 1: eligible participants will be randomized 1:1 to IMVT-1402 Dose 1 or placebo SC QW for 12 weeks. Period 2: participants who completed Period 1 will receive IMVT-1402 Dose 1 SC QW for 14 weeks. Period 3: after completion of Period 2, participants will be re-randomized 1:1 to blinded IMVT-1402 Dose 1 or Dose 2 SC QW for 26 weeks.
Conditions
- Subacute Cutaneous Lupus Erythematosus
- Chronic Cutaneous Lupus Erythematosus
Interventions
IMVT-1402Drug
Dose 1 or Dose 2 SC QW
PlaceboDrug
Matching Placebo SC QW
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change from Period 1 Baseline in Cutaneous Lupus Erythematosus Disease area and Severity Index activity (CLASI-A) score at Week 12Time frame: Baseline (Day 1) and Week 12
Locations
86 sites in 13 countries. Site status is shown where the registry gives one.
Site Number - 1010
Anniston, Alabama
Site Number - 1020
Birmingham, Alabama
Site Number - 1038
Phoenix, Arizona
Site Number - 1034
Scottsdale, Arizona
Site Number - 1022
Beverly Hills, California
Site Number - 1018
Chula Vista, California
Site Number - 1039
Corona, California
Site Number - 1005
Fremont, California
Site Number - 1023
Los Angeles, California
Site Number - 1000
Aurora, Colorado
Site Number - 1033
Castle Rock, Colorado
Site Number - 1021
Farmington, Connecticut
Site Number - 1014
Hialeah, Florida
Site Number - 1017
Jacksonville, Florida
Site Number - 1028
Miami, Florida
Site Number - 1024
Miami, Florida
Site Number - 1027
Miami, Florida
Site Number - 1011
Miami Lakes, Florida
Site Number - 1025
Orlando, Florida
Site Number - 1009
Buford, Georgia
Site Number - 1030
Brighton, Massachusetts
Site Number - 1019
Auburn Hills, Michigan
Site Number - 1003
Saint Clair Shores, Michigan
Site Number - 1013
Troy, Michigan
Site Number - 1004
Saint Joseph, Missouri
Site Number - 1026
St Louis, Missouri
Site Number - 1007
Charlotte, North Carolina
Site Number - 1008
Durham, North Carolina
Site Number - 1006
Smithfield, North Carolina
Site Number - 1002
Hershey, Pennsylvania
Site Number - 1015
Philadelphia, Pennsylvania
Site Number - 1035
Houston, Texas
Site Number - 1012
Irving, Texas
Site Number -5004
CABA, Argentina
Site Number - 5000
CABA, Argentina
Site Number - 5001
CABA, Argentina
Site Number - 5002
San Miguel de Tucumán, Argentina
Site Number - 5003
San Miguel de Tucumán, Argentina
Site Number - 5601
Sofia, Bulgaria
Site Number - 5603
Sofia, Bulgaria
Showing 40 of 86 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.